Table 1.
Ref. | Study type | Subject number | Therapy | Compared with | Duration | NAFLD vs NASH | Liver enzymes | Histology |
Marchesini et al[32] | Open label, single arm | 20 | Metformin | Baseline | 4 mo | NASH | Improved | Not assessed |
Nair et al[33] | Open label, Single arm | 15 | Metformin | Baseline | 48 wk | NAFLD | Transiently improved | Mildly improved |
Uygun et al[34] | Open label, RCT | 36 | Metformin | Diet/Exercise | 6 mo | NASH | Improved | Not improved |
Bugianesi et al[35] | Open label, RCT | 110 | Metformin | Vitamin E/Diet | 12 mo | NAFLD | Improved | Improved |
Duseja et al[36] | Open label, RCT | 50 | Metformin | Diet | 6 mo | NAFLD | Improved | Not assessed |
de Oliveira et al[37] | Open label, Single arm | 20 | Metformin and NAC | Baseline | 12 mo | NASH | Improved | Improved |
Loomba et al[38] | Open label, Single arm | 28 | Metformin | Baseline | 48 wk | NASH | Improved | Improved |
Haukeland et al[39] | Open label, RCT | 48 | Metformin | Diet/Exercise | 6 mo | NAFLD | Improved | Not improved |
Garinis et al[40] | Open label, RCT | 50 | Metformin | Diet | 6 mo | NAFLD | Improved | Not assessed |
Shargorodsky et al[41] | Open label, RCT | 63 | Metformin | Placebo | 12 mo | NAFLD | Not improved | Not assessed |
NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; RCT: Randomized controlled trials.